Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease therapies, has announced its participation in the virtual Lytham Partners Fall 2024 Investor Conference. Dr. Shalabh Gupta, the company's CEO, will engage in a fireside chat on October 1, 2024, at 11:00 a.m. ET.

Investors and interested parties can access the live webcast and archived recording through the Unicycive website's Investor section under Events and Presentations. The archived webcast will remain available for three months following the event, providing an extended opportunity for those unable to attend the live session.

News Market Reaction – UNCY

+2.82%

+2.82% Session move

In the trading session that priced this news, UNCY gained 2.82%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024 at 11:00 a.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.

Investor Contact:

ir@unicycive.com
(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics (UNCY) participating in the Lytham Partners Fall 2024 Investor Conference?

Unicycive Therapeutics (UNCY) is participating in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 11:00 a.m. ET.

Who will represent Unicycive Therapeutics (UNCY) at the Lytham Partners Fall 2024 Investor Conference?

Dr. Shalabh Gupta, the Chief Executive Officer of Unicycive Therapeutics, will represent the company in a fireside chat at the conference.

How can investors access the Unicycive Therapeutics (UNCY) presentation at the Lytham Partners Fall 2024 Investor Conference?

Investors can access the live and archived webcast of the presentation through the Unicycive website under the Investors section: Events and Presentations.

How long will the archived webcast of Unicycive Therapeutics' (UNCY) presentation be available?

The archived webcast of Unicycive Therapeutics' presentation will be available for three months following the event.

What is the main focus of Unicycive Therapeutics (UNCY) as a biotechnology company?

Unicycive Therapeutics (UNCY) is a clinical-stage biotechnology company developing therapies for patients with kidney disease.